About argenx SE
https://www.argenx.comargenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
CEO
Timothy Van Hauwermeiren
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 109
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 18
Price Target
Institutional Ownership
FMR LLC
Shares:5.69M
Value:$4.55B
PRICE T ROWE ASSOCIATES INC /MD/
Shares:3.64M
Value:$2.91B
JANUS HENDERSON GROUP PLC
Shares:2.58M
Value:$2.06B
Summary
Showing Top 3 of 527
About argenx SE
https://www.argenx.comargenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $947.96M ▲ | $636.15M ▲ | $245.36M ▲ | 25.88% ▲ | $6.85 ▲ | $513.95M ▲ |
| Q1-2025 | $790.68M ▼ | $570.94M ▲ | $169.47M ▼ | 21.43% ▼ | $2.78 ▼ | $203.5M ▲ |
| Q4-2024 | $1.35B ▲ | $562.71M ▲ | $865.57M ▲ | 64.29% ▲ | $14.44 ▲ | $126.61M ▲ |
| Q3-2024 | $573.24M ▼ | $499.98M ▲ | $91.41M ▲ | 15.95% ▲ | $1.52 ▲ | $88.7M ▲ |
| Q2-2024 | $901.94M | $495.01M | $-32.53M | -3.61% | $-0.55 | $-21.47M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $3.93B ▲ | $7.18B ▲ | $1.08B ▲ | $6.1B ▲ |
| Q4-2024 | $3.38B ▲ | $6.2B ▲ | $704.24M ▲ | $5.5B ▲ |
| Q2-2024 | $3.1B ▼ | $4.8B ▲ | $534.31M ▲ | $4.26B ▲ |
| Q4-2023 | $3.18B ▲ | $4.54B ▲ | $444.95M ▲ | $4.1B ▲ |
| Q2-2023 | $2B | $3.19B | $335.74M | $2.86B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $418.15M ▼ | $437.85M ▲ | $-10.31M ▲ | $74.08M ▼ | $586.04M ▲ | $432.61M ▲ |
| Q4-2024 | $865.57M ▲ | $41.91M ▲ | $-203.84M ▲ | $239.69M ▲ | $61.69M ▲ | $40.92M ▲ |
| Q2-2024 | $-32.48M ▲ | $-124.66M ▲ | $-513.76M ▼ | $40.07M ▼ | $-610.6M ▼ | $-125.47M ▲ |
| Q4-2023 | $-155.63M ▼ | $-134.89M ▲ | $-218.81M ▼ | $1.27B ▲ | $938.28M ▲ | $-135.22M ▲ |
| Q2-2023 | $-123.44M | $-258.5M | $500.47M | $62.29M | $263.67M | $-262.01M |
Revenue by Geography
| Region | Q2-2021 | Q2-2022 | Q2-2023 | Q4-2023 |
|---|---|---|---|---|
 EMEA | $0 ▲ | $0 ▲ | $20.00M ▲ | $50.00M ▲ |
 JAPAN | $0 ▲ | $0 ▲ | $20.00M ▲ | $30.00M ▲ |
 UNITED STATES | $0 ▲ | $90.00M ▲ | $440.00M ▲ | $610.00M ▲ |
 Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| C | $150.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Countries Other Than United States And China | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| U | $320.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Timothy Van Hauwermeiren
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 109
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 18
Price Target
Institutional Ownership
FMR LLC
Shares:5.69M
Value:$4.55B
PRICE T ROWE ASSOCIATES INC /MD/
Shares:3.64M
Value:$2.91B
JANUS HENDERSON GROUP PLC
Shares:2.58M
Value:$2.06B
Summary
Showing Top 3 of 527